Greenland Mines Ltd
GRML Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2022โFY2025
Last close ยท Oct 23, 2026
$5.78
3.3%What Greenland Mines Ltd does
No business description yet.
- Legal name
- Greenland Mines Ltd
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Apr 1, 2026
- Accession ยท CIK
- 0001213900-26-038629
0001907223
Revenue and margins
Greenland Mines Ltd had โ of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Greenland Mines Ltd returned โ to shareholders in fiscal 2025. The diluted share count rose 151.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Greenland Mines Ltd can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.3M | $0.0M | $0.1M | $7.2M |
| Interest coverage | โ | โ8.3x | โ15.5x | โ3.1x |
| Current ratio | 0.9x | 0.0x | 0.1x | 95.0x |
| Quick ratio | 0.9x | 0.0x | 0.1x | 95.0x |
| Total assets | $118M | $2.2M | $2.5M | $9.6M |
| Total liabilities | $4.9M | $1.6M | $1.3M | $0.1M |
| Shareholders' equity | โ$4.0M | โ$0.4M | $1.2M | $9.5M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | โ / 6 | โ / 6 |
| Accruals ratio | 1.5% | โ0.4% | โ137.8% | โ77.4% |
| Altman Z'' | โ1.01 | โ12.89 | โ31.09 | 69.31 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | โ | $0.0M | $0.0M | $0.6M |
| Operating income | โ$0.7M | โ$0.6M | โ$5.5M | โ$7.1M |
| Interest expense | โ | $0.1M | $0.4M | $2.3M |
| Pretax income | $1.6M | โ$0.7M | โ$6.2M | โ$10.6M |
| Income tax | $0.3M | $0.7M | โ | โ |
| Net income | $1.2M | โ$0.7M | โ$6.2M | โ$10.6M |
| Diluted EPS | โ | โ$0.05 | โ$0.32 | โ$0.22 |
| Diluted shares | โ | 0.02B | 0.02B | 0.05B |
| Cash flow | ||||
| Cash from operations | โ$0.5M | โ$0.4M | โ$2.9M | โ$5.9M |
| Stock-based compensation | โ | $0.0M | $2.6M | $1.6M |
| Balance sheet | ||||
| Cash and short-term investments | $0.3M | $0.0M | $0.1M | $7.2M |
| Deposits | โ | $0.0M | โ | โ |
| Current assets | $0.4M | $0.0M | $0.2M | $7.3M |
| Current liabilities | $0.5M | $1.6M | $1.2M | $0.1M |
| Intangible assets | โ | $2.2M | โ | $2.3M |
| Total assets | $118M | $2.2M | $2.5M | $9.6M |
| Total liabilities | $4.9M | $1.6M | $1.3M | $0.1M |
| Shareholders' equity | โ$4.0M | โ$0.4M | $1.2M | $9.5M |
| Returns | ||||
| Return on capital employed | โ0.6% | โ110.4% | โ457.9% | โ75.1% |
| Return on equity | โ | โ | โ1,656.5% | โ198.2% |
| Return on assets | 1.0% | โ1.2% | โ264.5% | โ175.1% |
| Return on tangible equity | โ | โ | โ518.9% | โ147.3% |
| Growth | ||||
| Net income growth | โ | โ157.4% | โ | โ |
| Share count change | โ | โ | 27.2% | 151.9% |
| Financial health | ||||
| Interest coverage | โ | โ8.3x | โ15.5x | โ3.1x |
| Current ratio | 0.9x | 0.0x | 0.1x | 95.0x |
| Quick ratio | 0.9x | 0.0x | 0.1x | 95.0x |
| Quality scores | ||||
| Altman Z'' | โ1.0 | โ12.9 | โ31.1 | 69.3 |
| Accruals ratio | 1.5% | โ0.4% | โ137.8% | โ77.4% |
Source: SEC EDGAR XBRL filings (CIK 0001907223). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.
